| P50 | author | Kimio Yonesaka | Q88448810 |
| | Junji Tsurutani | Q88448814 |
| P2093 | author name string | Kazuhiko Nakagawa | |
| | Kazuto Nishio | |
| | Osamu Maenishi | |
| | Takao Tamura | |
| | Kazuko Sakai | |
| | Naoki Takegawa | |
| | Yoshikane Nonagase | |
| | Yusuke Ogitani | |
| P2860 | cites work | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| | Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 |
| | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 |
| | Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer | Q27851691 |
| | Trastuzumab emtansine for HER2-positive advanced breast cancer | Q27851917 |
| | Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 |
| | Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 |
| | Trastuzumab emtansine: mechanisms of action and drug resistance | Q33759627 |
| | The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer | Q36545226 |
| | HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer | Q36772167 |
| | Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity | Q37098302 |
| | Assessment of a HER2 scoring system for gastric cancer: results from a validation study | Q37142266 |
| | HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target | Q37149210 |
| | Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1. | Q37709032 |
| | HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas | Q38474138 |
| | Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib | Q38876644 |
| | Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments | Q38913644 |
| | Mechanisms of Resistance to Antibody-Drug Conjugates | Q38990767 |
| | Antibody-maytansinoid conjugates designed to bypass multidrug resistance | Q39733184 |
| | DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant | Q41094672 |
| | HER2 aberrations in cancer: implications for therapy | Q44936056 |
| | Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. | Q51741363 |
| | DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. | Q54204362 |
| | Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. | Q54342129 |
| | Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. | Q54578578 |
| | Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update | Q57130157 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1682-1689 | |
| P577 | publication date | 2017-07-12 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance | |
| P478 | volume | 141 | |